Fri, Dec 26, 2014, 7:17 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Questcor Pharmaceuticals, Inc. (QCOR) Message Board

  • indianabraden indianabraden Apr 30, 2013 8:00 PM Flag

    Management telegraphed a potential record Q to come -


    I think it trades up.
    I liked the rheumatology numbers and growth rate.
    I liked the FDA accepted IND Phase 2 for MS with potential for Orphan Status.
    They explained quite clearly that this Q's numbers - and I see this as a continuing year-over-year growth victory - were influenced by a transition that actually represents more growth on the other end of it (temporary channel disruption, Medicare reimbursement changes, and reimbursement center being established for a much more scale in terms of volume of claims), buyt they were quite clear regarding being back on a fast growth track with a record April, so this Q is rear-view, and in my view, they've given us 1/3 of the picture for the next Q. The fact that they have not bought back shares in Q1, combined with a resumption of blowout numbers potentially next Q as stated (April's numbers) in their PR, I see that statement as a shot across the bow to the short interest. Going into a potential record Q with the ability to support and put upward pressure on the PPS with the removal of shares from the float THIS Q means 2 things: a potential floor supported by that program and a higher EPS (less shares with a resumption of high sales). The shorts are starting their covering tonight and new interest has taken advantage of the brief pull back to go long. With major long institutional ownership and Questcor potentially loading up on shares in the next two months, and with new interest coming in potentially on imminent upgrades, the pps will likely cklimb into earnings more steadily as there could potentially be a long slow short capitulation here. I believe the strength of the short story is dissipating after the list of constructive components to the Q and the clear disclosure of resumption of high sales in April. The Phase 2 ALS Trial adds a new component as well. Very positive.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
93.600.00(0.00%)Aug 14 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.